Poor financial performance associated with risk contracting between medical groups and insurers appears to be a thing of the past, according to “Capitation and Risk Contracting Survey” from ECG Management Consultants and the American Medical Group Association (AMGA).

More than half of medical groups characterized their organizations’ financial performance in risk contracts over the past two years as above average or excellent, with less than 10 percent citing poor financial performance. Seventy-five physician groups participated in the survey.

Thirty-six percent of participants reported that revenue derived from risk contracts is greater than half of their organization’s total revenue, and 33 percent said that less than 10 percent of revenue comes from risk contracts. Primary care and professional capitation are the most common contract types.

Physician groups tend to participate in primary care capitation with commercial HMO and point-of-service (POS) plans, but not with Medicare Advantage plans.

Capitation is a fixed monthly amount paid to a provider for each patient treated regardless of the volume of services rendered. Risk contracting occurs when a contracting organization entering into a capitation arrangement assumes the risk of delivering agreed services to a covered population at a contracted amount.

Primary care capitation covers services in a primary care physician’s office. In professional capitation, a medical group receives payments for services provided by both primary care doctors and by specialty physicians. Global capitation occurs when networks of hospitals and physicians band together to receive single fixed monthly payments for health plan members. In carve-out capitation, a managed care organization contracts with specialists to deliver specialty care required by members.

Source: ECG Management Consultants and the American Medical Group Association. “Capitation and Risk Contracting Survey”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.